Jason Rhodes Biography and Net Worth

Director of Dyne Therapeutics

Jason is a partner with Atlas Venture, where he focuses on creating and building novel therapeutics companies. He is a founder and the chairman of Dyne, Generation Bio (NASDAQ: GBIO), Rectify Pharmaceuticals, and Disarm Therapeutics (acquired by Lilly). He was also previously on the board of Replimune (NASDAQ: REPL).

Jason received his B.A. from Yale University and his M.B.A. from the Wharton School of the University of Pennsylvania.

What is Jason P. Rhodes' net worth?: The estimated net worth of Jason P. Rhodes is at least $258.62 thousand as of April 21st, 2026. Mr. Rhodes owns 13,148 shares of Dyne Therapeutics stock worth more than $258,621 as of April 23rd. This net worth approximation does not reflect any other assets that Mr. Rhodes may own. Learn More about Jason P. Rhodes' net worth.
How do I contact Jason P. Rhodes?: The corporate mailing address for Mr. Rhodes and other Dyne Therapeutics executives is 1560 Trapelo Road, Waltham, MA 02451, United States. Dyne Therapeutics can also be reached via phone at 781-786-8230 and via email at [email protected]. Learn More on Jason P. Rhodes' contact information.
Has Jason P. Rhodes been buying or selling shares of Dyne Therapeutics?: During the last ninety days, Jason P. Rhodes has sold $16,478,554.46 in Dyne Therapeutics stock. Most recently, Jason P. Rhodes sold 287,956 shares of the business's stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $19.68, for a transaction totalling $5,666,974.08. Following the completion of the sale, the director now directly owns 11,663 shares of the company's stock, valued at $229,527.84. Learn More on Jason P. Rhodes' trading history.
Who are Dyne Therapeutics' active insiders?: Dyne Therapeutics' insider roster includes Oxana Beskrovnaya (Chief Scientific Officer), Joshua Brumm (CEO), John Cox (President & CEO), Wildon Farwell (Insider), Johanna Friedl-Naderer (Chief Commercial Officer), Susanna High (COO), Carlo Incerti (Director), Dirk Kersten (Director), Jason Rhodes (Director), and Richard Scalzo (Insider). Learn More on Dyne Therapeutics' active insiders.
Are insiders buying or selling shares of Dyne Therapeutics?: During the last year, Dyne Therapeutics insiders bought shares 2 times. They purchased a total of 103,000 shares worth more than $956,180.00. During the last year, insiders at the sold shares 4 times. They sold a total of 836,942 shares worth more than $16,513,956.86. The most recent insider tranaction occured on April, 22nd when Director Jason P Rhodes sold 287,956 shares worth more than $5,666,974.08. Insiders at Dyne Therapeutics own 14.1% of the company. Learn More about insider trades at Dyne Therapeutics.
Information on this page was last updated on 4/22/2026.

Jason P. Rhodes Insider Trading History at Dyne Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/22/2026	Sell	287,956	$19.68	$5,666,974.08	11,663
4/21/2026	Sell	274,297	$19.52	$5,354,277.44	13,148
4/20/2026	Sell	272,049	$20.06	$5,457,302.94	14,561
11/14/2024	Sell	782	$33.10	$25,884.20	15,962
2/28/2024	Sell	190,920	$24.84	$4,742,452.80	864,487
2/26/2024	Sell	248,219	$23.72	$5,887,754.68	903,527
2/22/2024	Sell	119,360	$22.66	$2,704,697.60	6,512,104
2/20/2024	Sell	169,539	$22.72	$3,851,926.08	6,815,965
2/15/2024	Sell	177,906	$23.89	$4,250,174.34	7,148,211
12/12/2022	Buy	934,581	$10.70	$10,000,016.70	934,581

Jason P. Rhodes Buying and Selling Activity at Dyne Therapeutics

Dyne Therapeutics Company Overview

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $18.91

$18.27

$19.47

50 Day Range

MA: $17.58

$14.60

$20.41

2 Week Range

Now: $18.91

$8.06

$25.00

Volume

345,975 shs

Average Volume

2,144,887 shs

Market Capitalization

$3.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29